Drawing for IOMX

USPTO serial 79419666

IOMX

Reviewed by CopyMark Law Group

Status 641Office Action
Filing date
Status date
Registration date
—
Examiner
BLUE, MICHALA J
Law office
TMO LAW OFFICE 129

What this means

The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.

Status 641: Status 641 means the USPTO mailed a non-final Office Action identifying issues with your application. You typically have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.

Need help with IOMX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Alisa C. Simmons

Alisa C. Simmons Fitch, Even, Tabin & Flannery LLP120 S. LaSalle StreetChicago, IL 60603United States

Goods and services

ClassDescriptionStatusFirst use
001Chemical preparations for scientific and general industrial manufacturing purposes; Biochemical preparations, namely, genetically engineered polypeptides, for scientific purposes and proteins in raw material form for scientific and medical research, in particular antibodies and antibody-like polypeptides and proteins, and nucleic acid coding sequences for these for scientific purposes, in particular artificial polypeptides and proteins and nucleic acid coding sequences for these for scientific purposes; diagnostic preparations, except for medical or veterinary use.ACTIVE—
005Pharmaceutical diagnostic medical and veterinary preparations; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of diseases, ailments and disorders in humans and animals, in particular circulatory, respiratory, endocrine, neurological, cardiovascular, nutritional, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, ailments and disorders and the treatment and prevention of complications associated with such diseases, ailments and disorders; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of illnesses, ailments and disorders in humans and animals, in particular bone, sensory organ, viral, urinary tract, kidney, metabolic and central nervous system diseases, complaints and disorders and the treatment or prevention of complications associated with such diseases, ailments and disorders; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or and prevention of diseases, ailments and disorders in humans and animals, in particular infectious, autoimmune or and immunological, cell proliferative and oncological diseases, ailments and disorders, cancers, tumours and metastases and the treatment and prevention of complications associated with such diseases, ailments and disorders; pharmaceutical preparations and formulations and medical health preparations, in particular artificial polypeptides and proteins, in particular antibodies and antibody-like polypeptides and proteins, and nucleic acid coding for these, in particular for use in the following areas: treatment and prevention of various types of cancer, inflammatory diseases and autoimmune diseases; diagnostic preparations and biomarker reagents for medical and veterinary purposes; diagnostic preparations and diagnostic biomarker reagents for the diagnosis and prognosis of human and animal diseases, ailments and disorders, in particular circulatory, respiratory, endocrine, neurological, cardiovascular, nutritional, pulmonary, musculoskeletal, lymphatic or and gastrointestinal diseases, ailments and disorders and the diagnosis and prognosis in relation to complications associated with such diseases, ailments and disorders; diagnostic preparations and diagnostic biomarker reagents for medical purposes, namely, for the diagnosis and prognosis of human and animal diseases, ailments and disorders, in particular bone, sensory organ, virus, urinary tract, kidney, metabolic and central nervous system diseases, ailments and disorders and the diagnosis and prognosis in relation to complications associated with such diseases, ailments and disorders; diagnostic preparations and diagnostic biomarker reagents for medical purposes, namely, for the diagnosis and prognosis of diseases, ailments and disorders in humans and animals, in particular infectious, autoimmune and immunological, cell proliferative and oncological diseases, ailments and disorders, cancers, tumours and metastases and the diagnosis and prognosis in relation to complications associated with such diseases, ailments and disorders.ACTIVE—
042Scientific services, namely, scientific research in the field of biology, chemistry or medicine, as well as immunology, oncology, molecular biology, cell biology, biochemistry and medicinal chemistry, and relating to the discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic agents and diagnostic biomarker reagents and diagnostic apparatus; conducting early evaluations in the field of new pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; development of platform technology, namely a cancer immunotherapy platform for the production of therapeutics; chemical, biological and biochemical laboratory services; conducting chemical, biochemical and biological analyses; Medical and scientific research in the field of cancer diagnostics for scientific purposes; Biological and biochemical research laboratory services; Forensic pathological biological and biochemical examination services; providing technical and scientific research information in the field of biotechnology about a biotechnology company, its technologies, projects, product candidates, products and services via a web site on a global computer network; software design and development; design and development of computer software for use in the fields of biology, chemistry or medicine, in particular immunology, oncology, molecular biology, cellular biology, biochemistry and medicinal chemistry, as well as in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents and diagnostic apparatus.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 3, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Aug 19, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Aug 19, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Jun 16, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 16, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 16, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 26, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 26, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 26, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 27, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 27, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 27, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 27, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 27, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 27, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 15, 2025RFNTREFUSAL PROCESSED BY IB—
Jul 29, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jul 29, 2025RFRRREFUSAL PROCESSED BY MPU—
Jun 8, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 6, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 4, 2025DOCKASSIGNED TO EXAMINER—
Mar 21, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 21, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 20, 2025REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance